Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H44O |
Molecular Weight | 384.6377 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)CCC3=C)[C@H](C)CCCC(C)C
InChI
InChIKey=QYSXJUFSXHHAJI-YRZJJWOYSA-N
InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1
Molecular Formula | C27H44O |
Molecular Weight | 384.6377 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 2 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.drugbank.ca/drugs/DB00169
Curator's Comment: description was created based on several sources, including
http://www.drugbank.ca/drugs/DB00169
Cholecalciferol (/ˌkoʊləkælˈsɪfərɒl/) (vitamin D3) is one of the five forms of vitamin D. Cholecalciferol is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, in mineralization of bone, and for the assimilation of Vitamin A. The classical manifestation of vitamin D deficiency is rickets, which is seen in children and results in bony deformities including bowed long bones. Most people meet at least some of their vitamin D needs through exposure to sunlight. Ultraviolet (UV) B radiation with a wavelength of 290–320 nanometers penetrates uncovered skin and converts cutaneous 7-dehydrocholesterol to previtamin D3, which in turn becomes vitamin D3. In supplements and fortified foods, vitamin D is available in two forms, D2 (ergocalciferol) and D3 (cholecalciferol) that differ chemically only in their side-chain structure. Vitamin D2 is manufactured by the UV irradiation of ergosterol in yeast, and vitamin D3 is manufactured by the irradiation of 7-dehydrocholesterol from lanolin and the chemical conversion of cholesterol. The two forms have traditionally been regarded as equivalent based on their ability to cure rickets and, indeed, most steps involved in the metabolism and actions of vitamin D2 and vitamin D3 are identical. Both forms (as well as vitamin D in foods and from cutaneous synthesis) effectively raise serum 25(OH) D levels. Firm conclusions about any different effects of these two forms of vitamin D cannot be drawn. However, it appears that at nutritional doses, vitamins D2 and D3 are equivalent, but at high doses, vitamin D2 is less potent. The American Academy of Pediatrics (AAP) recommends that exclusively and partially breastfed infants receive supplements of 400 IU/day of vitamin D shortly after birth and continue to receive these supplements until they are weaned and consume ≥1,000 mL/day of vitamin D-fortified formula or whole milk. Cholecalciferol is used in diet supplementary to treat Vitamin D Deficiency. Cholecalciferol is inactive: it is converted to its active form by two hydroxylations: the first in the liver, the second in the kidney, to form calcitriol, whose action is mediated by the vitamin D receptor, a nuclear receptor which regulates the synthesis of hundreds of enzymes and is present in virtually every cell in the body. Calcitriol increases the serum calcium concentrations by increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1977 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20435140 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
42 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18326608/ |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CALCIDIOL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
968.6 nM × day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18326608/ |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CALCIDIOL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15.5 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18326608/ |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CALCIDIOL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
100000 unit single, oral Highest studied dose Dose: 100000 unit Route: oral Route: single Dose: 100000 unit Sources: |
healthy, 27-84 years n = 30 Health Status: healthy Age Group: 27-84 years Sex: M+F Population Size: 30 Sources: |
|
200 ug 1 times / day multiple, oral Highest studied dose Dose: 200 ug, 1 times / day Route: oral Route: multiple Dose: 200 ug, 1 times / day Sources: |
healthy, 33.4 ± 6.6 years n = 25 Health Status: healthy Age Group: 33.4 ± 6.6 years Sex: M+F Population Size: 25 Sources: |
|
100000 unit single, intramuscular Dose: 100000 unit Route: intramuscular Route: single Dose: 100000 unit Sources: |
healthy, 34.9 ± 9.1 years n = 12 Health Status: healthy Age Group: 34.9 ± 9.1 years Sex: M+F Population Size: 12 Sources: |
|
2000000 unit single, oral Overdose Dose: 2000000 unit Route: oral Route: single Dose: 2000000 unit Sources: |
unhealthy, 90-95 years n = 2 Health Status: unhealthy Age Group: 90-95 years Sex: M+F Population Size: 2 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/10219964/ Page: 3.0 |
strong | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/10219964/ Page: 3.0 |
yes [Ki 10 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/10219964/ Page: 3.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/15353333/ Page: 2.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15353333/ Page: 2.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15353333/ Page: 2.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15353333/ Page: 2.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15353333/ Page: 2.0 |
yes |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23612780
Purified T lymphocytes from 14 patients with systemic lupus erythematosus (SLE) and 13 healthy controls were cultured for 48 h in the presence and absence of 1 and 100 nM doses of vitamin D3.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:56:34 GMT 2023
by
admin
on
Sat Dec 16 17:56:34 GMT 2023
|
Record UNII |
1C6V77QF41
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
M05BB03
Created by
admin on Sat Dec 16 17:56:36 GMT 2023 , Edited by admin on Sat Dec 16 17:56:36 GMT 2023
|
||
|
NCI_THESAURUS |
C941
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
WHO-ATC |
M05BB05
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
ADROVANCE (AUTHORIZED: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
FOSAVANCE (AUTHORIZED: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
LOINC |
33958-0
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
DSLD |
207 (Number of products:385)
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
WHO-ATC |
M05BB08
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
WHO-VATC |
QM05BB03
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
WHO-VATC |
QM05BX53
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
CFR |
21 CFR 172.380
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
WHO-ATC |
M05BX53
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
LOINC |
87671-4
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
VANTAVO (AUTHORIZED: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
LOINC |
1990-1
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
FDA ORPHAN DRUG |
348111
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
27
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
FDA ORPHAN DRUG |
342911
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
WHO-VATC |
QM05BB05
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
NDF-RT |
N0000006277
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
WHO-ATC |
A11CC05
Created by
admin on Sat Dec 16 17:56:36 GMT 2023 , Edited by admin on Sat Dec 16 17:56:36 GMT 2023
|
||
|
WHO-ATC |
A11CC55
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
EPA PESTICIDE CODE |
202901
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
DSLD |
2297 (Number of products:7402)
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
NDF-RT |
N0000175952
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
WHO-ATC |
M05BB04
Created by
admin on Sat Dec 16 17:56:36 GMT 2023 , Edited by admin on Sat Dec 16 17:56:36 GMT 2023
|
||
|
WHO-VATC |
QM05BB04
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
WHO-VATC |
QA11CC05
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
LIVERTOX |
NBK548094
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
||
|
WHO-ATC |
M05BB07
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00169
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
CHEMBL1042
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
1244014
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
ALTERNATIVE | |||
|
2840
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
1C6V77QF41
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
CHOLECALCIFEROL
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | Description: Colourless crystals or a white, crystalline powder; odourless.Solubility: Practically insoluble in water; soluble in ethanol (~750 g/l) TS, ether R.Category: Vitamin, antirachitic.Storage: Colecalciferol should be kept in a hermetically closed container, in an inert atmosphere, protected from light and storedat a temperature between 2? and 8?C.Additional information: Even in the absence of light, Colecalciferol is gradually degraded on exposure to a humid atmosphere, thedecomposition being faster at higher temperatures. | ||
|
C48194
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
200-673-2
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
5280795
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
820
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
1497
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
D002762
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
CHOLECALCIFEROL
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
1131009
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
28940
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
cholecalciferol
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
100000092724
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
m11486
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID6026294
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
2747
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
67-97-0
Created by
admin on Sat Dec 16 17:56:36 GMT 2023 , Edited by admin on Sat Dec 16 17:56:36 GMT 2023
|
PRIMARY | |||
|
SUB06794MIG
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
2418
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
1C6V77QF41
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY | |||
|
375571
Created by
admin on Sat Dec 16 17:56:37 GMT 2023 , Edited by admin on Sat Dec 16 17:56:37 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
DERIVATIVE -> PARENT |
|
||
|
EPIMER -> DIASTEREOISOMER |
HYDROXYL GROUP IN R CONFIGURATION COMPARED TO CHOLECALCIFEROL
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
||
|
METABOLITE ACTIVE -> PARENT |
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE ACTIVE -> PRODRUG |
The conversion of calcidiol to calcitriol is catalyzed by the enzyme 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1).
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
EPIMER OF 7-DEHYDROCHOLESTEROL [EP IMPURITYB]
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|